Ralph R. Weichselbaum, MD
Emboldened by strong evidence from a mounting number of positive trials, investigators are growing confident that localized therapy in oligometastatic disease across cancers may soon lead to a new staging system and become standard of care (SOC). The tasks ahead are to learn more about why some patients respond better than others and to improve patient selection.
Figure 1. Inefficient Metastatic Process Provides A Window For Localized Curative Therapy1
Figure 2. Goals of Localized Therapy Oligometastatic Disease3
... to read the full story